Relapse prevention in schizophrenia with new-generation antipsychotics: a systematic review and exploratory meta-analysis of randomized, controlled trials.
about
Effectiveness of second generation antipsychotics: a systematic review of randomized trialsTime to discontinuation of atypical versus typical antipsychotics in the naturalistic treatment of schizophreniaMaintenance treatment with antipsychotic drugs for schizophreniaPharmacologic treatment of schizophreniaDiscontinuation of treatment of schizophrenic patients is driven by poor symptom response: a pooled post-hoc analysis of four atypical antipsychotic drugs.Randomized controlled trials in schizophrenia: opportunities, limitations, and trial design alternatives[Concept and results of the German Research Network on Schizophrenia].World Federation of Societies of Biological Psychiatry (WFSBP) guidelines for biological treatment of schizophrenia, Part 1: acute treatment of schizophrenia.World Federation of Societies of Biological Psychiatry (WFSBP) guidelines for biological treatment of schizophrenia, part 2: long-term treatment of schizophrenia.Allopurinol as adjuvant therapy in poorly responsive or treatment refractory schizophrenia.Psychosis and violence: stories, fears, and reality.Appraising evidence for intervention effectiveness in early psychosis: conceptual framework and review of evaluation approaches.Definitions and drivers of relapse in patients with schizophrenia: a systematic literature reviewAssessing social-cognitive deficits in schizophrenia with the Mayer-Salovey-Caruso Emotional Intelligence Test.Long-Acting Injectable Paliperidone Palmitate: A Review of Efficacy and Safety.Prevention of schizophrenia relapse with extended release quetiapine fumarate dosed once daily: a randomized, placebo-controlled trial in clinically stable patients.Relapse according to antipsychotic treatment in schizophrenic patients: a propensity-adjusted analysis.Depot Typical Antipsychotics versus Oral Atypical Antipsychotics in Relapse Rate Among Patients with Schizophrenia: A Five -Year Historical Cohort StudyModern antipsychotic drugs: a critical overviewChange in level of productivity in the treatment of schizophrenia with olanzapine or other antipsychoticsSchizophrenia (maintenance treatment).Maintenance treatment with quetiapine versus discontinuation after one year of treatment in patients with remitted first episode psychosis: randomised controlled trial.Schizophrenia: overview and treatment options.A randomised controlled study of risperidone and olanzapine for schizophrenic patients with neuroleptic-induced acute dystonia or parkinsonism.A systematic review of meta-analyses of the efficacy of oral atypical antipsychotics for the treatment of adult patients with schizophrenia.World Federation of Societies of Biological Psychiatry (WFSBP) guidelines for biological treatment of schizophrenia, part 2: update 2012 on the long-term treatment of schizophrenia and management of antipsychotic-induced side effects.Adjunctive lisdexamfetamine dimesylate therapy in adult outpatients with predominant negative symptoms of schizophrenia: open-label and randomized-withdrawal phases.Structural brain changes associated with antipsychotic treatment in schizophrenia as revealed by voxel-based morphometric MRI: an activation likelihood estimation meta-analysisQuality of life is predictive of relapse in schizophrenia.Methodological issues in current antipsychotic drug trials.What CATIE found: results from the schizophrenia trial.Ziprasidone vs olanzapine in recent-onset schizophrenia and schizoaffective disorder: results of an 8-week double-blind randomized controlled trialSecond-generation antipsychotic medications and risk of pneumonia in schizophrenia.Past and present progress in the pharmacologic treatment of schizophrenia.Preventing the second episode: a systematic review and meta-analysis of psychosocial and pharmacological trials in first-episode psychosisThe German Research Network on Schizophrenia--impact on the management of schizophreniaThe management of schizophrenia: focus on extended-release quetiapine fumarate.High relapse rate and poor medication adherence in the Chinese population with schizophrenia: results from an observational survey in the People's Republic of China.Brain in flames - animal models of psychosis: utility and limitationsNovel antipsychotics in the long-term treatment of schizophrenia.
P2860
Q21260262-CC3DC7AB-00F0-4059-BA2A-222DE15B7053Q21260279-76FC64CD-FF6A-4B5C-B499-C3BC69315795Q24197902-4E1AFB77-0340-42D0-964C-A5CFEDCA74C6Q24604457-7CBCDF48-8FAC-45F8-B7CE-6AFD4BC0A239Q25257471-4F852199-8FD2-445D-A200-A600AA21EC8BQ26863435-23900330-D37B-4980-BF58-70242B94BF3AQ30489053-89F51CA4-6B69-49D1-A96A-3B0AF191C827Q33223628-C063C5BC-1DA5-415A-9D04-7C9A46B0B052Q33235110-F8F7B30B-6A2A-405C-9D0D-29D4BD291A3CQ33264264-E17A473F-44DE-4141-95A3-85EF239764A4Q33378374-26E0F4C0-F11E-4343-80B6-D13DAD4140C5Q33533853-F9E10715-9234-4CE1-8DFF-9C4A69006485Q33589087-E5049465-4546-4C35-95D3-09EBF1962FB9Q33707629-DC02CDCF-B326-4B14-9B89-9A90925B3568Q33802918-087F7321-2E29-4727-9176-9E0ABBCCB534Q33814003-C4754867-F701-4EE2-B04B-F82AE1F7BFE3Q33818732-8E9301D6-F265-4858-AA5C-372164122A05Q33834476-E0F75BAB-5603-4545-8BFA-DCAF32D7CFB7Q33853390-AB082E80-3794-4859-925F-AC0FBE1955C4Q33903511-06247C9E-17AB-4CF1-AC28-3944A450E58CQ34010697-E245D23D-3F03-4E23-BC0E-5807BE791374Q34075734-4792071E-6F3B-4833-91DA-779EE3DA6114Q34154951-38F3C9A2-EE83-4641-AD6A-869D714BDDE8Q34183522-CD97929A-3790-418D-842C-B38A4DDD9DE7Q34224372-6D033766-3508-429C-979A-D6267A7572C9Q34315836-52094B06-0448-4457-AF09-5886A68DB977Q34350145-934B77E6-9184-4910-92CF-D8189F196A6CQ34393431-474F04AC-CBF7-4053-8EB8-863B74DC01C4Q34542824-E308EFE8-CD9E-4B77-8A25-053650029878Q34587745-5331433E-4DD5-416E-A707-0E57562D1D35Q34591378-0EA06229-D3A6-4616-9365-46861628BEABQ34604314-97A09E4F-DFDC-4B5F-9976-B1FD58EE9B51Q34635425-BC7C22C1-B159-4A10-8A10-2CF3EB41999EQ34726953-1B5FE95A-D90C-481E-90DA-D07D05BDE52CQ34830869-B25332E0-BB5B-491C-BD6F-5B2D570CC95AQ35236670-9313721C-62B0-4079-B524-7CD014481E88Q35327044-DDF7FFD4-FCEF-471D-9BDC-CA68BA03D0ABQ35605892-79DA65B1-8B5A-4D3A-AE62-377E12175592Q35683865-5AA78AB8-2911-4C01-A01B-6478875E7EACQ35719339-D6045C53-9D76-4875-95FA-3F3FCAAA7856
P2860
Relapse prevention in schizophrenia with new-generation antipsychotics: a systematic review and exploratory meta-analysis of randomized, controlled trials.
description
2003 nî lūn-bûn
@nan
2003 թուականի Յուլիսին հրատարակուած գիտական յօդուած
@hyw
2003 թվականի հուլիսին հրատարակված գիտական հոդված
@hy
2003年の論文
@ja
2003年論文
@yue
2003年論文
@zh-hant
2003年論文
@zh-hk
2003年論文
@zh-mo
2003年論文
@zh-tw
2003年论文
@wuu
name
Relapse prevention in schizoph ...... randomized, controlled trials.
@ast
Relapse prevention in schizoph ...... randomized, controlled trials.
@en
type
label
Relapse prevention in schizoph ...... randomized, controlled trials.
@ast
Relapse prevention in schizoph ...... randomized, controlled trials.
@en
prefLabel
Relapse prevention in schizoph ...... randomized, controlled trials.
@ast
Relapse prevention in schizoph ...... randomized, controlled trials.
@en
P2093
P1476
Relapse prevention in schizoph ...... randomized, controlled trials
@en
P2093
Christoph Correll
John M Kane
Stefan Leucht
Thomas R E Barnes
Werner Kissling
P304
P356
10.1176/APPI.AJP.160.7.1209
P407
P577
2003-07-01T00:00:00Z